Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 11/20 | 0.46 |
| ▸ | PPARA | Q07869 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19252776 | 0.90 | REN (0.46) | RENPPARANPC1LMNAHTT | |
| SCHEMBL19272912 | 0.89 | L3MBTL1 (0.46) | RENLMNAL3MBTL1NPSR1MEN1 | |
| SCHEMBL17709394 | 0.89 | REN (0.45) | RENPPARANPC1LMNAHTT | |
| SCHEMBL16930243 | 0.88 | REN (0.48) | RENPPARANPC1LMNAHTT | |
| SCHEMBL17709308 | 0.87 | SMPD1 (0.48) | RENKMT2ASMPD1MTNR1AMTNR1B | |
| SCHEMBL17709371 | 0.87 | REN (0.47) | RENPPARANPC1LMNAHTT | |
| SCHEMBL29613180 | 0.87 | REN (0.47) | RENPPARANPC1LMNAHTT | |
| SCHEMBL17721710 | 0.86 | PPARA (0.38) | RENPPARALMNAHTTL3MBTL1 | |
| SCHEMBL19087141 | 0.84 | LMNA (0.44) | NPC1LMNAHTTNPSR1MEN1 | |
| SCHEMBL17709303 | 0.84 | SMPD1 (0.52) | NPC1MEN1HPGDKMT2ASMPD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3215504-B1 | 6,7-DIHYDROBENZO[A]QUINOLIZIN-2-ONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN LA ROCHE (CH) | 2019-08-21 | — | — | EP | disclosed |
| EP-3215504-B1 | 6,7-DIHYDROBENZO[A]QUINOLIZIN-2-ONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN LA ROCHE (CH) | 2019-08-21 | — | — | EP | disclosed |
| EP-3215504-A1 | NOVEL 6,7-DIHYDROBENZO[A]QUINOLIZIN-2-ONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. Hoffmann-La Roche AG (CH) | 2017-09-13 | — | — | EP | disclosed |
| WO-2017114812-A1 | COMBINATION THERAPY OF AN HBSAG INHIBITOR AND AN INTERFERON | F. HOFFMANN-LA ROCHE AG (CH) | 2017-07-06 | — | — | WO | disclosed |
| WO-2017114812-A1 | COMBINATION THERAPY OF AN HBSAG INHIBITOR AND AN INTERFERON | F. HOFFMANN-LA ROCHE AG (CH) | 2017-07-06 | — | — | WO | disclosed |
| WO-2017108630-A1 | COMBINATION THERAPY OF AN HBSAG INHIBITOR AND AN HBV CAPSID ASSEMBLY INHIBITOR | F. HOFFMANN-LA ROCHE AG (CH) | 2017-06-29 | — | — | WO | disclosed |
| WO-2017108630-A1 | COMBINATION THERAPY OF AN HBSAG INHIBITOR AND AN HBV CAPSID ASSEMBLY INHIBITOR | F. HOFFMANN-LA ROCHE AG (CH) | 2017-06-29 | — | — | WO | disclosed |
| WO-2017102648-A1 | COMBINATION THERAPY OF AN HBSAG INHIBITOR AND A NUCLEOS(T)IDE ANALOGUE | F. HOFFMANN-LA ROCHE AG (CH) | 2017-06-22 | — | — | WO | disclosed |
| WO-2017102648-A1 | COMBINATION THERAPY OF AN HBSAG INHIBITOR AND A NUCLEOS(T)IDE ANALOGUE | F. HOFFMANN-LA ROCHE AG (CH) | 2017-06-22 | — | — | WO | disclosed |
| US-9637485-B2 | 6,7-dihydrobenzo[a]quinolizin-2-one derivatives for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2017-05-02 | — | — | US | disclosed |
| US-9637485-B2 | 6,7-dihydrobenzo[a]quinolizin-2-one derivatives for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2017-05-02 | — | — | US | disclosed |
| US-9637485-B2 | 6,7-dihydrobenzo[a]quinolizin-2-one derivatives for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2017-05-02 | — | — | US | disclosed |
| WO-2016071215-A1 | NOVEL 6,7-DIHYDROBENZO[A]QUINOLIZIN-2-ONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2016-05-12 | — | — | WO | disclosed |
| US-20160122344-A1 | Novel 6,7-dihydrobenzo[a]quinolizin-2-one derivatives for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2016-05-05 | — | — | US | disclosed |
| US-20160122344-A1 | Novel 6,7-dihydrobenzo[a]quinolizin-2-one derivatives for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2016-05-05 | — | — | US | disclosed |
| US-20160122344-A1 | Novel 6,7-dihydrobenzo[a]quinolizin-2-one derivatives for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2016-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160122344-A1 | Novel 6,7-dihydrobenzo[a]quinolizin-2-one derivatives for the treatment and prophylaxis of hepatitis B virus infection | HAVCR2, SLC10A1, CYP2D6 | REN 25/4885PPARA 2359/4885NPC1 430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.